Pharmacological validity of amlodipine, lisinopril and rosuvastatin in three-component combination drug products
- Authors: Giliarevskiy S.R1, Golshmid M.V1, Kuzmina I.M2, Zakharova G.Y.1, Sinitsina I.I1
-
Affiliations:
- Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
- N.V.Sklifosovsky Research Institute of Emergency Medicine of the Department of Health of Moscow
- Issue: Vol 18, No 10 (2016)
- Pages: 66-70
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/94588
- ID: 94588
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
S. R Giliarevskiy
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation
Email: sgilarevsky@rambler.ru
д-р мед. наук, проф. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
M. V Golshmid
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
I. M Kuzmina
N.V.Sklifosovsky Research Institute of Emergency Medicine of the Department of Health of Moscowканд. мед. наук, зав. науч. отд-нием неотложной кардиологии ГБУЗ НИИ СП им. Н.В.Склифосовского 129090, Russian Federation, Mosсow, Bol'shaia Sukharevskaia pl., d. 3
G. Yu Zakharova
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federationканд. мед. наук, доц. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
I. I Sinitsina
Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federationд-р мед. наук, проф. каф. клин. фармакологии и терапии ГБОУ ДПО РМАПО 125993, Russian Federation, Moscow, ul. Barrikadnaia, d. 2/1
References
- Roth G.A, Forouzanfar M.H, Moran A.E et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med 2015; 372: 1333-41.
- Lewington S, Clarke R, Qizilbash N et al. Age - specific relevance of usual blood pressure to vascular mortality: a meta - analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-13.
- Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case - control study. Lancet 2004; 364: 937-52.
- Rose G. Strategy of prevention: lessons from cardiovascular disease. Br Med J (Clin Res Ed) 1981; 282: 1847-51.
- Wald N.J, Law M.R. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326: 1419.
- Chapman R.H, Benner J.S, Petrilla A.A et al. Predictors of adherence with antihypertensive and lipid - lowering therapy. Arch Intern Med 2005; 165: 1147-52.
- Li W, Zeng S, Yu L.S, Zhou Q. Pharmacokinetic drug interaction profle of omeprazole with adverse consequences and clinical risk management. Ther Clin Risk Manag 2013; 9: 259-71.
- Olsson A.G, Mc Taggart F, Raza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-28.
- Hua W.J, Hua W.X, Fang H.J. The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins. Cardiovasc Ther 2012; 30: e234-e241.
- Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008; 36: 2014-23.
- Kock K, Brouwer K.L. A perspective on efflux transport proteins in the liver. Clin Pharmacol Ther 2012; 92: 599-612.
- Niemi M, Pasanen M.K, Neuvonen P.J. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-81.
- AstraZeneca. Crestor (rosuvastatin) [prescribing information]. http://www1.astrazeneca-us.com/pi/crestor.pdf. Accessed November 3, 2015.
- Crestor tablets. AccessdataFDA. http://www.accessdata. fda.gov/drugsatfda_docs/label/2005/21366slr005lbl.pdf. Accessed June 3, 2016.
- Boehringer Ingelheim. Twynsta (telmisartan/amlodipine) [prescribing information]. www.accessdata.fda.gov/drug satfda_docs/label/2014/ 022401s016lbl.pdf. Accessed November 3, 2015.
- Abernethy D.R. Pharmacokinetics and pharmacodynamics of amlodipine. Cardiology 1992; 80 (Suppl. 1): 31-6.
- Nishio S, Watanabe H, Kosuge K et al. Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. Hypertens Res 2005; 28: 223-7.
- Park C.G, Lee H, Choi J.W et al. Non - concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin. Int J Clin Pharmacol Ther 2010; 48: 497-503.
- Son H, Lee D, Lim L.A et al. Development of a pharmacokinetic interaction model for co - administration of simvastatin and amlodipine. Drug Metab Pharmacokinet 2014; 29: 120-8.
- Zhou Y.T, Yu L.S, Zeng S et al. Pharmacokinetic drug - drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management. Ther Clin Risk Manag 2014; 10: 17-26.
- Dresser G.K, Spence J.D, Bailey D.G. Pharmacokinetic - pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38: 41-57.
- Kerr K.P, Mate K.E, Magin P.J et al. The prevalence of co - prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community - dwelling elderly Australians. J Clin Pharm Ther 2014; 39: 383-9.
- Ulm E.H, Hichens M, Gomez H.J et al. Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br J Clin Pharmac 1982; 14: 357-62.
- Gomez H.J, Cirillo V.J, Moncloa F. The clinical pharmacology of lisinopril. J Сardiovasc Pharmac 1987; 9 (Suppl. 3): S27-S34.
- Wang Y.C, Hsieh T.C, Chou C.L et al. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population - Based Study. Medicine (Baltimore) 2016; 95 (2): e2487.
- Son H, Lee D, Lim L.A et al. Development of a pharmacokinetic interaction model for co - administration of simvastatin and amlodipine. Drug Metab Pharmacokinet 2014; 29: 120-8.
- Zhou Y.T, Yu L.S, Zeng S et al. Pharmacokinetic drug - drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management. Ther Clin Risk Manag 2014; 10: 17-26.
- Sever P.S, Dahlöf B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - than - average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
- Pedersen T.R, Faergeman O, Kastelein J.J et al. High-Dose Atorvastatin vs Usual - Dose Simvastatin for Secondary Prevention After Myocardial Infarction: The IDEAL Study: A Randomized Controlled Trial. JAMA 2005; 294: 2437-45.
- Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25: 20-58.
- Sun J.X, Cipriano A, Chan K, John V.A. Pharmacokinetic interaction study between benazepril and amlodipine in healthy subjects. Eur J Clin Pharmacol 1994; 47: 285-9.
- Zheng X, Liu T, Chen X et al. Investigation of a potential pharmacokinetic interaction between perindopril arginine and amlodipine when administered as a single perindopril/amlodipine fixed - dose combination tablet in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 2016; 54: 43-51.
- Son M, Guk J, Kim Y et al. Pharmacokinetic Interaction Between Rosuvastatin, Telmisartan, and Amlodipine in Healthy Male Korean Subjects: A Randomized, Open - label, Multiple - dose, 2-period Crossover Study. Clin Ther 2016. Jul 12 [Epub ahead of print].
- Kennedy-Dixon T.G, Gossell-Williams M, Hall J, Anglin-Brown B. The prevalence of major potential drug - drug interactions at a University health centre pharmacy in Jamaica. Pharm Pract (Granada) 2015; 13: 601.
- Teixeira J.J, Crozatti M.T, dos Santos C.A, Romano-Lieber N.S. Potential drug - drug interactions in prescriptions to patients over 45 years of age in primary care, southern Brazil. PLoS One 2012; 7: e47062.
- Kónyi A, Sárszegi Z, Hild G, Gaszner B. Safety and effectiveness of combined antihypertensive and cholesterol - lowering therapy in high-/very high - risk patients. J Comp Eff Res 2016; 5: 355-64.